Clinical research of sitagliptin combined with metformin for treating obese patients with type 2 diabetes

Objective To investigate the clinical effect of sitagliptin combined with metformin for treating obese patients with type 2 diabetes. Methods A total of 86 cases of obesity, poor glycemic controlling and newly diagnosed type 2 diabetes patients were randomly divided into two groups. The patients of two groups were given diabetic diet and took regular exercise. In addition, the control group were treated with acarbose combined with metformin while the treatment group were treated with sitagliptincombined with metformin for 12 weeks. The glycosylated hemoglobin(HbA1c), fasting plasma glucose(FPG), 2 hours postprandial blood glucose(2 h FPG), triglycerides(TG), total cholesterol(TC), lowdensity lipoprotein cholesterol(LDL-C), high density lipoprotein cholesterol(HDL-C), body mass index(BMI) and pancreatic β-cell function index(HOMA-β) were detected. Results The FPG, 2 h FPG, HbA1c and BMI of the treatment group after treatment were significantly lower than those of the control group(t =13.73,6.57,13.17,59.53,P 0.05) while the difference of HOMA-β was not statistically significant(t =1.10,P 0.05). The differences of TC, TG, LDL-C and HDL-C after treatment between the treatment group and control group were statistically significant(t=12.26, 7.75, 4.73, 4.03, P0.05). Conclusion Sitagliptin combined with metformin can effectively reduce blood glucose and lipid and control weight. It is an effective treatment for obese patients with type 2 diabetes.